Cargando…

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry

Detalles Bibliográficos
Autores principales:	Selvarajah, Abi, Tavenier, Annerieke H, Bor, Wilbert L, Houben, Vital, Rasoul, Saman, Kaplan, Eliza, Teeuwen, Koen, Hofma, Sjoerd H, Lipsic, Erik, Amoroso, Giovanni, van Leeuwen, Maarten A H, ten Berg, Jur M, van ‘t Hof, Arnoud W J, Hermanides, Renicus S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242080/ https://www.ncbi.nlm.nih.gov/pubmed/35923807 http://dx.doi.org/10.1093/ehjopen/oeab028

Ejemplares similares

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry
por: Selvarajah, A., et al.
Publicado: (2021)

Efficacy of Cangrelor as Bridging Therapy Post PCI
por: Khan, Abdul A., et al.
Publicado: (2020)

Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
por: De Luca, Leonardo, et al.
Publicado: (2021)

Cangrelor Use in Routine Practice: A Two-Center Experience
por: van der Sangen, Niels M. R., et al.
Publicado: (2021)

Complementary Pharmacotherapy for STEMI Undergoing Primary PCI: An Evidence-Based Clinical Approach
por: Fabris, Enrico, et al.
Publicado: (2022)

Cangrelor bridging strategy for liver damage after mechanical chest compression
por: Cereda, Alberto Francesco, et al.
Publicado: (2019)

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
por: Cavender, Matthew A., et al.
Publicado: (2016)

Cangrelor ameliorates CLP-induced pulmonary injury in sepsis by inhibiting GPR17
por: Luo, Qiancheng, et al.
Publicado: (2021)

Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
por: O’Donoghue, Michelle L., et al.
Publicado: (2016)

Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome
por: Selvarajah, Abi, et al.
Publicado: (2022)

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX
por: Gutierrez, J. Antonio, et al.
Publicado: (2016)

Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients
por: Prüller, Florian, et al.
Publicado: (2018)

Safety of Low Dose Intravenous Cangrelor in Acute Ischemic Stroke: A Case Series
por: Salahuddin, Hisham, et al.
Publicado: (2021)

Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Urgent Revascularization of the Left Proximal Circumflex Following Cessation of Cangrelor Within Six Hours of Procedure
por: Huang, Sherri, et al.
Publicado: (2023)

P2Y(12) Receptor Function and Response to Cangrelor in Neonates With Cyanotic Congenital Heart Disease
por: Kaza, Elisabeth A., et al.
Publicado: (2017)

Efficacy of a Combined Antiplatelet Therapy Is Not Affected by a Simultaneous Binding of Cangrelor and PSB 0777 to Albumin
por: Wzorek, Joanna, et al.
Publicado: (2021)

Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study
por: Thim, Troels, et al.
Publicado: (2023)

The use of cangrelor with heparin for left ventricular assist device implantation in a patient with acute heparin-induced thrombocytopenia
por: Gernhofer, Yan K., et al.
Publicado: (2018)

The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX
por: Yong, Celina M., et al.
Publicado: (2019)

Antiplatelet strategy during ad-hoc percutaneous coronary intervention in elective patients: how aggressive should we be?
por: Selvarajah, Abi, et al.
Publicado: (2023)

Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus
por: Polak, Dawid, et al.
Publicado: (2021)

Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX
por: Cavender, Matthew A., et al.
Publicado: (2021)

Comparison of myocardial reperfusion between intracoronary versus intravenous cangrelor administration in patients undergoing primary percutaneous coronary intervention
por: Muraca, Iacopo, et al.
Publicado: (2023)

Sex Differences in Platelet Reactivity in Patients With ST-Elevation Myocardial Infarction: A Sub-Analysis of the ON-TIME 3 Trial
por: Tavenier, Anne H., et al.
Publicado: (2021)

Cardioprotective Properties of the Platelet P2Y(12) Receptor Inhibitor, Cangrelor: Protective in Diabetics and Reliant Upon the Presence of Blood
por: Bell, R. M., et al.
Publicado: (2015)

Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience
por: Rossini, Roberta, et al.
Publicado: (2020)

Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective
por: Jensen, Ivar S., et al.
Publicado: (2021)

Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study
por: De Luca, Leonardo, et al.
Publicado: (2022)

Safety of cangrelor and transition to oral P2Y(12) inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study
por: De Luca, Leonardo, et al.
Publicado: (2023)

Ticagrelor Versus Clopidogrel in Older Patients with NSTE-ACS Using Oral Anticoagulation: A Sub-Analysis of the POPular Age Trial
por: Gimbel, Marieke E., et al.
Publicado: (2020)

Cangrelor or Clopidogrel in Patients with Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
por: Lu, Hongtao, et al.
Publicado: (2019)

Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial
por: Gargiulo, Giuseppe, et al.
Publicado: (2020)

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
por: Capodanno, Davide, et al.
Publicado: (2019)

High Platelet Reactivity after Transition from Cangrelor to Ticagrelor in Hypothermic Cardiac Arrest Survivors with ST-Segment Elevation Myocardial Infarction
por: Buchtele, Nina, et al.
Publicado: (2020)

Comparative effectiveness of Cangrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational investigation from the M.O.Ca. registry
por: Pepe, Martino, et al.
Publicado: (2023)

Cangrelor Use Patterns and Transition to Oral P2Y(12) Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry
por: Rymer, Jennifer A., et al.
Publicado: (2022)

Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2016)

Safety and Efficacy of Cangrelor Among Three Antiplatelet Regimens During Stent-Assisted Endovascular Treatment of Unruptured Intracranial Aneurysm: A Single-Center Retrospective Study
por: Cheddad El Aouni, Mourad, et al.
Publicado: (2022)

The P2Y(12) Antagonists, 2MeSAMP and Cangrelor, Inhibit Platelet Activation through P2Y(12)/G(i)-Dependent Mechanism
por: Xiang, Binggang, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_5d6fnh4h6gvs77oqpie63tbp3p